Literature DB >> 31962285

Cancer immunotherapy: Pros, cons and beyond.

Shuzhen Tan1, Dongpei Li2, Xiao Zhu3.   

Abstract

Cancer immunotherapy is an innovative treatment for tumors today. In various experiments and clinical studies, it has been found that immunotherapy does have incomparable advantages over traditional anti-tumor therapy, which can prolong progression-free survival (PFS) and overall survival (OS). However, immunotherapy has obvious complexity and uncertainty. Immunotherapy may also cause severe adverse reactions due to an overactive immune system. More effective and fewer adverse reactions immunological checkpoints are still under further exploration. This review gives an overview of recent developments in immunotherapy and indicates a new direction of tumor treatment through analyzing the pros and cons of immunotherapy coupled with keeping a close watch on the development trend of the immunotherapy future.
Copyright © 2020 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  CAR-T; Cancer immunotherapy; Immune checkpoint inhibitors; PD-1; Tumor microenvironment

Mesh:

Substances:

Year:  2020        PMID: 31962285     DOI: 10.1016/j.biopha.2020.109821

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  65 in total

1.  Three-dimensional genome: developmental technologies and applications in precision medicine.

Authors:  Yingqi Li; Tao Tao; Likun Du; Xiao Zhu
Journal:  J Hum Genet       Date:  2020-03-09       Impact factor: 3.172

2.  Pan-cancer analysis of tumor mutation burden sensitive tumors reveals tumor-specific subtypes and hub genes related to immune infiltration.

Authors:  Huan Wu; Hanchu Wang; Yue Chen
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-02       Impact factor: 4.553

Review 3.  Reprogramming the tumor microenvironment to improve the efficacy of cancer immunotherapies.

Authors:  Jabar A Faraj; Ali Jihad Hemid Al-Athari; Sharaf El Din Mohie; Iman Kareem Kadhim; Noor Muhsen Jawad; Weaam J Abbas; Abduladheem Turki Jalil
Journal:  Med Oncol       Date:  2022-09-29       Impact factor: 3.738

4.  A single local delivery of paclitaxel and nucleic acids via an immunoactive polymer eliminates tumors and induces antitumor immunity.

Authors:  Fanfei Meng; Jianping Wang; Yanying He; Gregory M Cresswell; Nadia A Lanman; L Tiffany Lyle; Timothy L Ratliff; Yoon Yeo
Journal:  Proc Natl Acad Sci U S A       Date:  2022-05-24       Impact factor: 12.779

Review 5.  RNA-based therapies: A cog in the wheel of lung cancer defense.

Authors:  Parvez Khan; Jawed Akhtar Siddiqui; Imayavaramban Lakshmanan; Apar Kishor Ganti; Ravi Salgia; Maneesh Jain; Surinder Kumar Batra; Mohd Wasim Nasser
Journal:  Mol Cancer       Date:  2021-03-19       Impact factor: 27.401

Review 6.  Clinical translation of immunomodulatory therapeutics.

Authors:  Amanda Nash; Samira Aghlara-Fotovat; Andrea Hernandez; Christopher Scull; Omid Veiseh
Journal:  Adv Drug Deliv Rev       Date:  2021-07-27       Impact factor: 17.873

Review 7.  Employing Drug Delivery Strategies to Overcome Challenges Using TLR7/8 Agonists for Cancer Immunotherapy.

Authors:  Dhruv Varshney; Sherry Yue Qiu; Tyler P Graf; Kevin J McHugh
Journal:  AAPS J       Date:  2021-06-28       Impact factor: 4.009

8.  Factors associated with healthcare utilisation during first year after cancer diagnose-a population-based study.

Authors:  Helena Ullgren; Lena Sharp; Anna Olofsson; Per Fransson
Journal:  Eur J Cancer Care (Engl)       Date:  2020-11-20       Impact factor: 2.520

Review 9.  The Evolution of Cancer Immunotherapy.

Authors:  Meshaal Khan; Ajay V Maker; Shikha Jain
Journal:  Vaccines (Basel)       Date:  2021-06-08

Review 10.  Mesenchymal stem cells: ideal seeds for treating diseases.

Authors:  Guanwen Gao; Chenyang Fan; Weiquan Li; Runzhang Liang; Chuzhong Wei; Xiaojie Chen; Yue Yang; Yueyuan Zhong; Yingqi Shao; Yi Kong; Zesong Li; Xiao Zhu
Journal:  Hum Cell       Date:  2021-07-16       Impact factor: 4.374

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.